Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating systemic sclerosis in 2001.

L Mouthon1, C Agard

  • 1Internal Medicine Department, Hôpital Avicenne, Université Paris-Nord, Bobigny France. luc.mouthon@avc.ap-hop-paris.fr

Joint Bone Spine
|November 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Observance of antifibrotic treatment in the French OPALE support program for patients with pulmonary fibrosis].

Revue des maladies respiratoires·2026
Same author

Value of the chewing gum test for the diagnosis of giant cell arteritis: a multicentre pilot study.

Scandinavian journal of rheumatology·2026
Same author

[French internal medicine is at a turning point in its history. Summary of the 2024 French Internal Medicine meeting].

La Revue de medecine interne·2024
Same author

Identifying giant cell arteritis patients with higher risk of relapse and vascular events: a cluster analysis.

QJM : monthly journal of the Association of Physicians·2024
Same author

Outcome and prognosis of isolated carotid vasculitis.

Journal of autoimmunity·2024
Same author

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same journal

Greater trochanteric bursal distension with intra-bursal rice bodies: an unusual MRI presentation.

Joint bone spine·2026
Same journal

Evaluating the Impact of a Rheumatologist-led Comorbidity Review in Patients with Inflammatory Arthritis.

Joint bone spine·2026
Same journal

What cumulative glucocorticoid dose should trigger sparing strategies in polymyalgia rheumatica?

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

Joint bone spine·2026
Same journal

Multimodal imaging evaluation of the entheses in spondyloarthritis.

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update. What's new?

Joint bone spine·2026
See all related articles

Systemic sclerosis (SS) treatments show limited long-term efficacy. Current options focus on managing symptoms and emerging therapies like cyclophosphamide and stem cell transplants for specific organ involvement.

Area of Science:

  • Rheumatology
  • Internal Medicine
  • Dermatology

Background:

  • Systemic sclerosis (SS) involves skin and organ hardening and vascular issues.
  • Current long-term treatments for SS offer limited efficacy and survival benefits.
  • Conventional therapies, including D-penicillamine, have shown disappointing results in clinical practice.

Purpose of the Study:

  • To review effective long-term treatment strategies for Systemic Sclerosis.
  • To highlight emerging therapies for diffuse SS and specific organ involvement.
  • To suggest tailored symptomatic treatment approaches for SS complications.

Main Methods:

  • Review of current literature on Systemic Sclerosis treatments.
  • Analysis of prospective randomized studies on treatment efficacy.

Related Experiment Videos

  • Focus on emerging therapies and symptomatic management strategies.

    • Main Results:

    • Limited efficacy of conventional drug treatments for Systemic Sclerosis.
    • Emerging treatments like cyclophosphamide and stem cell transplantation show promise for specific SS manifestations.
    • Symptomatic treatments (ACE inhibitors, calcium channel blockers, PPIs) remain crucial for managing SS complications.

    Conclusions:

    • Long-term treatment efficacy for Systemic Sclerosis remains a significant challenge.
    • Cyclophosphamide and stem cell transplantation represent new avenues for diffuse SS.
    • Personalized symptomatic management is key to addressing organ-specific issues in SS.